Market Analysts see VistaGen Therapeutics Inc. [VTGN] gaining to $6. Time to buy?

VistaGen Therapeutics Inc. [NASDAQ: VTGN] price surged by 5.15 percent to reach at $0.03. The company report on August 13, 2020 that VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress.

Company Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Subsequent to Quarter-end.

Positive Meeting with the FDA Sets Key Aspects of Pivotal PH94B Phase 3 Study.

A sum of 2747646 shares traded at recent session while its average daily volume was at 2.39M shares. VistaGen Therapeutics Inc. shares reached a high of $0.7627 and dropped to a low of $0.69 until finishing in the latest session at $0.73.

The one-year VTGN stock forecast points to a potential upside of 27.0. The average equity rating for VTGN stock is currently 2.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on VistaGen Therapeutics Inc. [VTGN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VTGN shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VTGN stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Maxim Group have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 27, 2018. While these analysts kept the previous recommendation, Chardan Capital Markets dropped their target price from $30 to $22. The new note on the price target was released on February 08, 2018, representing the official price target for VistaGen Therapeutics Inc. stock. Previously, the target price had yet another raise to $4, while Maxim Group analysts kept a Buy rating on VTGN stock.

The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.10

VTGN Stock Performance Analysis:

VistaGen Therapeutics Inc. [VTGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.09. With this latest performance, VTGN shares dropped by -3.27% in over the last four-week period, additionally plugging by 7.52% over the last 6 months – not to mention a rise of 20.32% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 47.83, with the RSI for the last a single of trading hit 43.68, and the three-weeks RSI is set at 50.66 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 0.6614, while it was recorded at 0.7536 for the last single week of trading, and 0.5904 for the last 200 days.

Insight into VistaGen Therapeutics Inc. Fundamentals:

Return on Total Capital for VTGN is now -725.79, given the latest momentum, and Return on Invested Capital for the company is -819.37. Return on Equity for this stock declined to -3,087.23, with Return on Assets sitting at -210.01.

Reflecting on the efficiency of the workforce at the company, VistaGen Therapeutics Inc. [VTGN] managed to generate an average of -$2,308,222 per employee.VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.80.


With the latest financial reports released by the company, VistaGen Therapeutics Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VTGN.

VistaGen Therapeutics Inc. [VTGN] Insider Position Details

There are presently around $2 million, or 9.40% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: VANGUARD GROUP INC with ownership of 1,165,317, which is approximately -3.452% of the company’s market cap and around 0.20% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 251,656 shares of the stock with an approximate value of $0.18 million in VTGN stocks shares; and ADVISOR GROUP HOLDINGS, INC., currently with $0.13 million in VTGN stock with ownership of nearly 0% of the company’s market capitalization.

Positions in VistaGen Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 8 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 269,303 shares. Additionally, 7 investors decreased positions by around 91,139 shares, while 13 investors held positions by with 2,243,136 shares. The mentioned changes placed institutional holdings at 2,603,578 shares, according to the latest SEC report filing. VTGN stock had 5 new institutional investments in for a total of 166,417 shares, while 3 institutional investors sold positions of 35,848 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam